Literature DB >> 20363001

Is pulmonary function damaged by neoadjuvant lung cancer therapy? A comprehensive serial time-trend analysis of pulmonary function after induction radiochemotherapy plus surgery.

S Margaritora1, A Cesario, G Cusumano, S Cafarotti, G M Corbo, L Ferri, M Ceppi, E Meacci, S Valente, R M D'Angelillo, P Russo, V Porziella, S Bonassi, F Pasqua, S Sterzi, P Granone.   

Abstract

OBJECTIVE: We have analyzed short- and long-term variations of pulmonary function in locally advanced non-small cell lung cancer after induction chemoradiotherapy.
METHODS: Twenty-seven patients with stage IIIA (N2) non-small cell lung cancer underwent resection with radical intent after induction chemoradiotherapy in the period 2003 to 2006. Pulmonary function has been evaluated by spirometry, diffusing capacity of the lung for carbon monoxide, and blood gas analysis before induction chemoradiotherapy (T0), 4 weeks after induction chemoradiotherapy and before surgery (T1), and 1 (T2), 3 (T3), 6 (T4), and 12 months (T5) after surgery.
RESULTS: A 22.80% decrease of diffusing capacity of the lung for carbon monoxide (P < .001) was observed at T1. At T2 significant decreases in the following were present: vital capacity, -20.50% (P < .001); forced vital capacity, -22.50% (P < .001); forced expiratory volume in 1 second, -23.00% (P < .001); peak expiratory flow, -29.0 (P < .001); forced expiratory flow 25% to 75%, -13.7% (P = .005); and diffusing capacity of the lung for carbon monoxide, 43.6% (P < .001). However, in the interval between T2 and T5, a progressive improvement of lung function in most parameters was observed, but only diffusing capacity of the lung for carbon monoxide presented a significant increase (P < .001). Within the same time gap (T2 to T5), subjects 65 years of age or younger showed an increasing trend for vital capacity, forced expiratory volume in 1 second, total lung capacity, and residual volume significantly different from that of elderly patients, in whom a decrease in these parameters is reported.
CONCLUSIONS: An impairment of respiratory function is evident in the immediate postoperative setting in patients with non-small cell lung cancer receiving induction chemoradiotherapy. In the long-term period, a general recovery in diffusing capacity of the lung for carbon monoxide was found, whereas an improvement of forced expiratory volume in 1 second, vital capacity, total lung capacity, and residual volume was detected in the younger population only. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20363001     DOI: 10.1016/j.jtcvs.2009.10.023

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer.

Authors:  Sai Yendamuri; Adrienne Groman; Austin Miller; Todd Demmy; Mark Hennon; Elisabeth Dexter; Anthony Picone; Chukwumere Nwogu; Grace K Dy
Journal:  Eur J Cardiothorac Surg       Date:  2018-03-01       Impact factor: 4.191

2.  Comparison of pulmonary function changes between patients receiving neoadjuvant chemotherapy and chemoradiotherapy prior to minimally invasive esophagectomy: a randomized and controlled trial.

Authors:  Xiaosang Chen; Mingjun Du; Han Tang; Hao Wang; Yong Fang; Miao Lin; Jun Yin; Lijie Tan; Yaxing Shen
Journal:  Langenbecks Arch Surg       Date:  2022-08-25       Impact factor: 2.895

3.  Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.

Authors:  James G Connolly; Megan Fiasconaro; Kay See Tan; Michael A Cirelli; Gregory D Jones; Raul Caso; Daniel E Mansour; Joseph Dycoco; Jae Seong No; Daniela Molena; James M Isbell; Bernard J Park; Matthew J Bott; David R Jones; Gaetano Rocco
Journal:  J Thorac Cardiovasc Surg       Date:  2021-12-23       Impact factor: 6.439

4.  Lung function changes after chemoradiation therapy in patients with lung cancer treated by three usual platinum combinations.

Authors:  Vasilios Mihailidis; Stavros Anevlavis; Georgia Karpathiou; George Kouliatsis; Argyrios Tzouvelekis; Paul Zarogoulidis; Paschalis Ntolios; Paschalis Steiropoulos; Demosthenes Bouros; Marios E Froudarakis
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

5.  [Correlation between pulmonary function indexes and survival time in patients with advanced lung cancer].

Authors:  Hui Ge; Zhenghua Jiang; Qian Huang; Muyun Zhu; Jie Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.